
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte demonstrated strong revenue growth driven by increased demand for Jakafi, which rose 10% year-over-year across all indications, alongside a successful commercial launch of Niktivmo. The company's dermatology product, Opzelura, reported growth ahead of expectations, with revenues reaching $188 million, attributed to rising patient demand for atopic dermatitis and vitiligo treatments. Incyte's raised full-year 2025 guidance to $4.23 billion - $4.32 billion reflects a positive outlook spurred by Jakafi's projecting revenues and contributions from other oncology products, highlighting the potential for continued commercial success.
Bears say
Incyte faces significant downside risks that could negatively impact its financial outlook, particularly concerning its leading drug, Jakafi. Key concerns include the erosion of pricing power for Jakafi, poor performance of the earlier-stage pipeline, and potential clinical or regulatory setbacks related to Jakafi combinations, which could adversely affect future revenue. Additionally, challenges such as competition, reimbursement issues, and safety signals from ongoing launches further exacerbate the company's risks, suggesting a decline in sales growth potential.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares